Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Cyclophosphamide · Frindovyx

Small molecule · Cytotoxic · developed by Baxter Hlthcare

Approved FDA, Nov 1959

3 Registered trials

What is Cyclophosphamide?

Cyclophosphamide is a synthetic alkylating agent that cross-links DNA and inhibits DNA replication, initiating cell death in rapidly proliferating malignant cells. It is also studied in chronic lymphocytic leukemia and metastatic melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Frindovyx
Drug type: Small molecule
Mechanism: Cytotoxic
Pathways: DNA cross-linking, DNA replication inhibition, apoptosis
Therapy area: Oncology
Developer: Baxter Hlthcare
In trials of: AAPG, IOVA
FDA status: Approved as Frindovyx (November 16, 1959), NDA012141 · FDA label

✅ FDA-approved uses

Hodgkin's disease
Lymphocytic lymphoma
Mixed-cell type lymphoma
Histiocytic lymphoma
Burkitt's lymphoma
Multiple myeloma
Chronic lymphocytic leukemia
Acute lymphoblastic leukemia

From the indications section of the FDA label (version of Aug 7, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06319456	Phase 3	CLL/SLL	Recruiting	AAPG
NCT07288073	Phase 2	Cutaneous Squamous Cell Carcinoma	Recruiting	IOVA
NCT01701674	N/A	Metastatic Melanoma	Completed	IOVA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CLL/SLLMetastatic Melanoma

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z